Following a limited submission
AWMSG advice |
|||
| Status: Recommended | |||
Indacaterol/glycopyrronium (Ultibro® Breezhaler®) is recommended as an option for use within NHS Wales as a maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease. |
|||
|
|||
Medicine details |
|||
| Medicine name | indacaterol / glycopyrronium (Ultibro® Breezhaler®) | ||
| Formulation | 85 micrograms/43 micrograms inhalation powder | ||
| Reference number | 1535 | ||
| Indication | Maintenance bronchodilator treatment to relieve symptoms in adult patients with chronic obstructive pulmonary disease |
||
| Company | Novartis Pharmaceuticals UK Ltd | ||
| BNF chapter | Respiratory system | ||
| Submission type | Limited | ||
| Status | Recommended | ||
| Advice number | 0814 | ||
| NMG meeting date | 22/01/2014 | ||
| AWMSG meeting date | 19/02/2014 | ||
| Ratification by Welsh Government | 07/05/2014 | ||
| Date of issue | 08/05/2014 | ||
| Date of last review | 08/05/2017 | ||